Proleukin (Prometheus Labs) recommended for treating Melanoma
Proleukin (aldesleukin for injection) / Interleukin-2, from Prometheus Labs, has been included in newly issued guidelines from the Society for Immunotherapy of Cancer (SITC) for the treatment of high risk and advanced- stage cutaneous Melanoma. The guidelines, which appear in the August 23rd issue of the journal Nature Reviews in Clinical Oncology, are the first evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with Melanoma.
See: "The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma." Kaufman H et al. Nature Reviews Clinical Oncology, August 27, 2013, 10.1038/nrclinonc.2013.153
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.